Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: a preliminary study.

Literature DB >> 23736947

Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: a preliminary study.

Heiko Ullrich¹, Laura Kranaster, Erich Sigges, Jürgen Andrich, Alexander Sartorius.

Abstract

Serum levels of neuron specific enolase (NSE) and protein S-100 were analysed in 22 patients with depression, who got repetitive transcranial magnetic stimulation (rTMS) for 3 weeks with ultra high frequency stimulation or sham. NSE and S-100 at baseline and after 3 weeks did not differ between the groups. Neither in the ultra high frequency group, nor in the sham group a difference between baseline and end could be found. No evidence for a significant rise in brain damage markers in rTMS was found in this preliminary study.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23736947 DOI： 10.1007/s00702-013-1050-9

Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575

21 in total

1. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996.

Authors: E M Wassermann
Journal: Electroencephalogr Clin Neurophysiol Date: 1998-01

Review 2. Astroglial 5-HT1a receptors and S-100 beta in development and plasticity.

Authors: P M Whitaker-Azmitia; E C Azmitia
Journal: Perspect Dev Neurobiol Date: 1994

3. Electroconvulsive therapy and biomarkers of neuronal injury and plasticity: Serum levels of neuron-specific enolase and S-100b protein.

Authors: Johanna Palmio; Martti Huuhka; Seppo Laine; Heini Huhtala; Jukka Peltola; Esa Leinonen; Jaana Suhonen; Tapani Keränen
Journal: Psychiatry Res Date: 2010-04-08 Impact factor: 3.222

4. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression.

Authors: M P Szuba; J P O'Reardon; A S Rai; J Snyder-Kastenberg; J D Amsterdam; D R Gettes; E Wassermann; D L Evans
Journal: Biol Psychiatry Date: 2001-07-01 Impact factor: 13.382

5. Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation.

Authors: Undine E Lang; Malek Bajbouj; Juergen Gallinat; Rainer Hellweg
Journal: Psychopharmacology (Berl) Date: 2006-04-22 Impact factor: 4.530

6. S100 and impact of ECT on depression and cognition.

Authors: Baer Arts; Maarten Peters; Rudolf Ponds; Adriaan Honig; Paul Menheere; Jim van Os
Journal: J ECT Date: 2006-09 Impact factor: 3.635

7. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients.

Authors: Roberta Zanardini; Anna Gazzoli; Mariacarla Ventriglia; Jorge Perez; Stefano Bignotti; Paolo Maria Rossini; Massimo Gennarelli; Luisella Bocchio-Chiavetto
Journal: J Affect Disord Date: 2006-01-31 Impact factor: 4.839

2. Protein S-100 and neuron-specific enolase serum levels remain unaffected by electroconvulsive therapy in patients with depression.

Authors: Laura Kranaster; Christoph Janke; Sonani Mindt; Michael Neumaier; Alexander Sartorius
Journal: J Neural Transm (Vienna) Date: 2014-05-07 Impact factor: 3.575

2 in total

Neuron specific enolase and serum remain unaffected by ultra high frequency left prefrontal transcranial magnetic stimulation in patients with depression: a preliminary study.

1. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996.

Review 2. Astroglial 5-HT1a receptors and S-100 beta in development and plasticity.

3. Electroconvulsive therapy and biomarkers of neuronal injury and plasticity: Serum levels of neuron-specific enolase and S-100b protein.

4. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression.

5. Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation.

6. S100 and impact of ECT on depression and cognition.

7. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients.

8. S100B and response to treatment in major depression: a pilot study.

9. Purification and characterization of human neuron-specific enolase: radioimmunoassay development.

10. S100B is increased in mood disorders and may be reduced by antidepressive treatment.

Review 1. Safety of noninvasive brain stimulation in children and adolescents.

2. Protein S-100 and neuron-specific enolase serum levels remain unaffected by electroconvulsive therapy in patients with depression.